Combination of antiviral drugs inhibits SARS-CoV-2 polymerase and exonuclease and demonstrates COVID-19 therapeutic potential in viral cell culture

SARS-CoV-2 has an exonuclease-based proofreader, which removes nucleotide inhibitors such as Remdesivir that are incorporated into the viral RNA during replication, reducing the efficacy of these drugs for treating COVID-19. Combinations of inhibitors of both the viral RNA-dependent RNA polymerase a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xuanting, Sacramento, Carolina Q., Jockusch, Steffen, Chaves, Otávio Augusto, Tao, Chuanjuan, Fintelman-Rodrigues, Natalia, Chien, Minchen, Temerozo, Jairo R., Li, Xiaoxu, Kumar, Shiv, Xie, Wei, Patel, Dinshaw J., Meyer, Cindy, Garzia, Aitor, Tuschl, Thomas, Bozza, Patrícia T., Russo, James J., Souza, Thiago Moreno L., Ju, Jingyue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8863796/
https://www.ncbi.nlm.nih.gov/pubmed/35194144
http://dx.doi.org/10.1038/s42003-022-03101-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8863796/
https://www.ncbi.nlm.nih.gov/pubmed/35194144
http://dx.doi.org/10.1038/s42003-022-03101-9

Ejemplares similares